The small-molecule pharmacological inhibitor ABR-238901 selectively targets S100A9 and has demonstrated efficacy in reducing infarct size and enhancing cardiac function in preclinical models of myocardial infarction. The gene discussed is S100A9; the disease is myocardial infarction.